
ABVC Valuation
ABVC Biopharma Inc
- Overview
- Forecast
- Valuation
- Earnings
ABVC Relative Valuation
ABVC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABVC is overvalued; if below, it's undervalued.
Historical Valuation
ABVC Biopharma Inc (ABVC) is now in the Fair zone, suggesting that its current forward PS ratio of 16.62 is considered Fairly compared with the five-year average of -5.89. The fair price of ABVC Biopharma Inc (ABVC) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:3.34
Fair
-0.72
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
ABVC Biopharma Inc. (ABVC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-3.88
EV/EBIT
ABVC Biopharma Inc. (ABVC) has a current EV/EBIT of -3.88. The 5-year average EV/EBIT is -5.45. The thresholds are as follows: Strongly Undervalued below -18.06, Undervalued between -18.06 and -11.75, Fairly Valued between 0.85 and -11.75, Overvalued between 0.85 and 7.15, and Strongly Overvalued above 7.15. The current Forward EV/EBIT of -3.88 falls within the Historic Trend Line -Fairly Valued range.
16.62
PS
ABVC Biopharma Inc. (ABVC) has a current PS of 16.62. The 5-year average PS is 130.36. The thresholds are as follows: Strongly Undervalued below -442.34, Undervalued between -442.34 and -155.99, Fairly Valued between 416.71 and -155.99, Overvalued between 416.71 and 703.07, and Strongly Overvalued above 703.07. The current Forward PS of 16.62 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
ABVC Biopharma Inc. (ABVC) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
-7.23
P/FCF
ABVC Biopharma Inc. (ABVC) has a current P/FCF of -7.23. The 5-year average P/FCF is -1.55. The thresholds are as follows: Strongly Undervalued below -5.78, Undervalued between -5.78 and -3.66, Fairly Valued between 0.57 and -3.66, Overvalued between 0.57 and 2.68, and Strongly Overvalued above 2.68. The current Forward P/FCF of -7.23 falls within the Strongly Undervalued range.
ABVC Biopharma Inc (ABVC) has a current Price-to-Book (P/B) ratio of 8.85. Compared to its 3-year average P/B ratio of 1.59 , the current P/B ratio is approximately 456.65% higher. Relative to its 5-year average P/B ratio of -0.28, the current P/B ratio is about -3295.05% higher. ABVC Biopharma Inc (ABVC) has a Forward Free Cash Flow (FCF) yield of approximately -2.99%. Compared to its 3-year average FCF yield of -35.71%, the current FCF yield is approximately -91.62% lower. Relative to its 5-year average FCF yield of -25.60% , the current FCF yield is about -88.31% lower.
8.85
P/B
Median3y
1.59
Median5y
-0.28
-2.99
FCF Yield
Median3y
-35.71
Median5y
-25.60
Competitors Valuation Multiple
The average P/S ratio for ABVC's competitors is 3.89, providing a benchmark for relative valuation. ABVC Biopharma Inc Corp (ABVC) exhibits a P/S ratio of 16.62, which is 326.78% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ABVC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ABVC in the past 1 year is driven by Unknown.
People Also Watch

PSTV
Plus Therapeutics Inc
0.558
USD
-11.15%

RKDA
Arcadia Biosciences Inc
4.650
USD
0.00%

EFOI
Energy Focus Inc
1.910
USD
0.00%

TGL
Treasure Global Inc
1.320
USD
+3.94%

HOLO
MicroCloud Hologram Inc
4.800
USD
+0.42%

BLMZ
Harrison Global Holdings Inc
0.194
USD
+7.17%

ATXG
Addentax Group Corp
0.475
USD
0.00%

FTFT
Future Fintech Group Inc
1.890
USD
0.00%

BGLC
BioNexus Gene Lab Corp
5.340
USD
0.00%
FAQ

Is ABVC Biopharma Inc (ABVC) currently overvalued or undervalued?
ABVC Biopharma Inc (ABVC) is now in the Fair zone, suggesting that its current forward PS ratio of 16.62 is considered Fairly compared with the five-year average of -5.89. The fair price of ABVC Biopharma Inc (ABVC) is between to according to relative valuation methord.

What is ABVC Biopharma Inc (ABVC) fair value?

How does ABVC's valuation metrics compare to the industry average?

What is the current P/B ratio for ABVC Biopharma Inc (ABVC) as of Aug 18 2025?

What is the current FCF Yield for ABVC Biopharma Inc (ABVC) as of Aug 18 2025?

What is the current Forward P/E ratio for ABVC Biopharma Inc (ABVC) as of Aug 18 2025?
